Citations

Mayo Clinic

Showing 10 of 108572 citations.

Outcomes of Atrial Fibrillation Ablation in Patients With and Without Chronic Kidney Disease Are No Different…. . Hmmm!
Deshmukh, Abhishek , Kancharla, Krishna

Journal of Cardiovascular Electrophysiology | November 16, 2016 | Volume: 28 | Issue: 1 | Pages: 49-50

10.1111/jce.13123 | PMID 27859930 Get It

Late outcomes of adult survivors of childhood non‐Hodgkin lymphoma: A report from the St. Jude Lifetime Cohort Study
Ehrhardt, Matthew J. , Sandlund, John T., Zhang, Nan , Liu, Wei , Ness, Kirsten K. , Bhakta, Nickhill , Chemaitilly, Wassim , Krull, Kevin R. , Brinkman, Tara M. , Crom, Deborah B., Kun, Larry E. , Kaste, Sue C. , Armstrong, Gregory T. , Srivastava, Kumar , Mulrooney, Daniel A. , Green, Daniel M. , Robison, Leslie L. , Hudson, Melissa M. , Mulrooney, Daniel A , Ness, Kirsten K , Bhakta, Nickhill

Pediatric Blood & Cancer | November 16, 2016 | Volume: 64 | Issue: 6 | Pages: No page available

10.1002/pbc.26338 | PMID 27860222 Get It

AbstractBackgroundSurvivors of childhood non‐Hodgkin lymphoma (NHL) are at increased risk for chronic health conditions. The objective of this study was to characterize health conditions, neurocognitive function, and physical performance among a clinically evaluated cohort of 200 childhood NHL survivors.MethodChronic health and neurocognitive conditions were graded as per a modified version of the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) and impaired physical function defined as performance < 10th percentile of normative data. Multivariable regression was used to investigate associations between sociodemographic characteristics, therapeutic exposures, and outcomes.ResultsSurvivors were a median age of 10 years (range 1–19) at diagnosis and 34 years (range 20–58) at evaluation. Eighty‐eight (44%) received radiation, 46 (23%) cranial radiation, and 69 (35%) high‐dose methotrexate. Most prevalent CTCAE Grades 3–4 (severe life‐threatening) conditions were obesity (35%), hypertension (9%), and impairment of executive function (13%), attention (9%), and memory (4%). Many had impaired strength (48%), flexibility (39%), muscular endurance (36%), and mobility (36%). Demographic and treatment‐related factors were associated with the development of individual chronic diseases and functional deficits.ConclusionsClinical evaluation identified a high prevalence of chronic health conditions, neurocognitive deficits, and performance limitations in childhood NHL survivors.
HLA‐DR polymorphisms influence in vivo responses to staphylococcal toxic shock syndrome toxin‐1 in a transgenic mouse model
Krogman, Ashton , Tilahun, Ashenafi Y. , David, Chella S., Chowdhary, Vaidehi , Alexander, Mariam P., Rajagopalan, Govindarajan

HLA | November 16, 2016 | Volume: 89 | Issue: 1 | Pages: 20-28

10.1111/tan.12930 | PMID 27863161 Get It

AbstractToxic shock syndrome toxin‐1 (TSST‐1) is a potent superantigen produced by Staphylococcus aureus. In addition to menstrual and nonmenstrual toxic shock syndromes, TSST‐1 is also implicated in the immunopathogenesis of pneumonia, infective endocarditis, neonatal exanthematous disease, and atopic dermatitis among others. Superantigens first bind to major histocompatibility complex (MHC) class II molecules and then activate a large proportion of T cells by cross‐linking their T cell receptor. As binding to MHC class II molecules is a critical step in the robust activation of the immune system by TSST‐1 and other superantigens, polymorphic variations between different HLA‐DR alleles could potentially influence the magnitude of immune activation and immunopathology caused by TSST‐1. As TSST‐1 is highly toxic to humans and given that multiple variations of alleles of HLA‐DR and HLA‐DQ are expressed in each individual, it is difficult to determine how HLA‐DR polymorphisms quantitatively and qualitatively impact immune activation caused by TSST‐1 in humans. However, such investigations can be conducted on transgenic mice lacking all endogenous MHC class II molecules and expressing specific HLA class II alleles. Therefore, transgenic mice expressing different HLA‐DRB1 alleles (HLA‐DRB1*15:01, HLA‐DRB1*15:02, HLA‐DRB1*03:01, HLA‐DRB1*04:01), and sharing HLA‐A1*01:01 chain, were systemically challenged with purified TSST‐1 and multiple immune parameters were assessed. Among the HLA‐DR alleles, mice expressing HLA‐DRB1*15:01 allele elicited a significantly higher serum cytokine/chemokine response; greater splenic T cell expansion and most severe organ pathology. Our study highlights the potential utility of human leukocyte antigen (HLA) transgenic mice in understanding the impact of HLA polymorphisms on the outcomes of diseases caused by TSST‐1 and other superantigens.
A microRNA biomarker panel for the non-invasive detection of bladder cancer
Urquidi, Virginia, Netherton, Mandy, Gomes-Giacoia, Evan, Serie, Daniel, Eckel‐Passow, Jeanette E. , Rosser, Charles J. , Goodison, Steve , Serie, Daniel J, Eckel-Passow, Jeanette

Oncotarget | November 16, 2016 | Volume: 7 | Issue: 52 | Pages: 86290-86299

10.18632/oncotarget.13382 | PMID 27863434 Get It

Periodontitis and risk of psoriasis: a systematic review and meta‐analysis
Ungprasert, Patompong , Wijarnpreecha, Karn , Wetter, David A. , Wijarnpreecha, Karn

Journal of the European Academy of Dermatology and Venereology | November 16, 2016 | Volume: 31 | Issue: 5 | Pages: 857-862

10.1111/jdv.14051 | PMID 27862342 Get It

AbstractBackgroundThe association between periodontitis and systemic diseases has been increasingly recognized. However, the data on the association between periodontitis and psoriasis are still limited.ObjectivesTo summarize all available data on the association between periodontitis and the risk of psoriasis.MethodsTwo investigators independently searched published studies indexed in MEDLINE and EMBASE databases from inception to July 2016 using a search strategy that included terms for psoriasis and periodontitis. Studies were included if the following criteria were met: (i) case–control or cohort study comparing the risk of psoriasis in subjects with and without periodontitis; (ii) subjects without periodontitis were used as comparators in cohort studies while participants without psoriasis were used as controls in case–control studies; and (iii) effect estimates and 95% confidence intervals (CI) were provided. Point estimates and standard errors from each study were extracted and combined together using the generic inverse variance technique described by DerSimonian and Laird.ResultsTwo cohort studies and three case–control studies met the inclusion criteria and were included in the meta‐analysis. The pooled risk ratio of psoriasis in patients with periodontitis versus comparators was 1.55 (95% CI, 1.35–1.77). The statistical heterogeneity was insignificant with an I2 of 18%. Subgroup analysis according to study design revealed a significantly higher risk among patients with periodontitis with a pooled RR of 1.50 (95% CI, 1.37–1.64) for cohort studies and a pooled RR of 2.33 (95% CI, 1.51–3.60) for case–control studies.ConclusionsPatients with periodontitis have a significantly elevated risk of psoriasis.
Evaluating the utility of serological testing in laryngotracheal stenosis
Hall, Stuart R., Meratı, Albert L., Mayerhoff, Ross , Hall, S Ryan, Allen, Clint T , Mayerhoff, Ross

The Laryngoscope | November 16, 2016 | Volume: 127 | Issue: 6 | Pages: 1408-1412

10.1002/lary.26385 | PMID 27861923 Get It

Early‐onset limb‐girdle muscular dystrophy‐2L in a female athlete
Blackburn, Patrick R. , Selcen, Duygu , Jackson, Jessica L. , Guthrie, Kimberly J., Cousin, Margot A. , Boczek, Nicole J. , Clift, Kristin , Klee, Eric W. , Dimberg, Elliot L., Clift, Kristin E, Atwal, Paldeep S. , Atwal, Paldeep S , Clift, Kristin E

Muscle & Nerve | November 16, 2016 | Volume: 55 | Issue: 5 | Pages: No page available

10.1002/mus.25471 | PMID 27862037 Get It

A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer
Iyer, Renuka , Pokuri, Venkata K., Groman, Adrienne , Ma, Wen W., Malhotra, Usha , Iancu, Dan M., Grande, Catherine, Bekaii‐Saab, Tanios , Saab, Tanios B, Ma, Wen W., Iancu, Dan M., Bekaii-Saab, Tanios S

American Journal of Clinical Oncology | November 16, 2016 | Volume: 41 | Issue: 7 | Pages: 649-655

10.1097/coc.0000000000000347 | PMID 27849649 Get It

Objectives: Vascular endothelial growth factor overexpression, seen in 42% to 76% of biliary tract cancers (BTCs), correlates with poor survival. We explored the safety/efficacy and potential biomarkers for bevacizumab in combination with gemcitabine-capecitabine in advanced BTCs. Patients and Methods: Inoperable stage III/IV BTC patients in our prospective study were given 1000 mg/m 2 of gemcitabine (on days 1, 8), 650 mg/m 2 of capecitabine (on days 1 to 14), and 15 mg/kg of bevacizumab (on day 1) in 21-day cycles. Circulating tumor cells and quality of life were assessed at baseline and before cycle 2 and 3. Results: In total, 50 patients with gallbladder cancer (22%), intrahepatic (58%), and extrahepatic (20%) cholangiocarcinoma, received a median of 8 treatment cycles for median treatment duration of 5.8 months. Common grade 3/4 toxicities were neutropenia (36%), thrombocytopenia (16%), fatigue (20%), infections (14%), and hand-foot syndrome (10%). There were 12 partial response (24%), 24 stable disease (48%) with clinical benefit rate of 72%. Median progression-free survival was 8.1 months (95% confidence interval, 5.3-9.9). Median overall survival was 10.2 months (95% confidence interval, 7.5-13.7). Circulating tumor cells were identified at baseline in 21/46 patients (46%), who had lower median overall survival compared with those without (9.4 vs. 13.7 mo; P =0.29). Patients with quality of life scores greater than the group median by the end of first cycle of treatment had improved survival compared with those who did not (13.3 vs. 9.4 mo; P =0.39). Conclusions: Addition of bevacizumab to gemcitabine/capecitabine did not improve outcome in an unselected group of patients with advanced BTC compared with historical controls. The selective benefit of vascular endothelial growth factor inhibition in BTC remains to be explored.
Estimating glomerular filtration rate for the full age spectrum from serum creatinine and cystatin C
Pottel, Hans , Delanaye, Pierre , Schäeffner, Elke , Dubourg, Laurence , Melsom, Toralf , Lamb, Edmund J. , Glassock, Richard J. , Souza, V. de , Selistre, Luciano da Silva , Goffin, Karolien , Pauwels, Steven , Mariat, Christophe , Flamant, Martin , Ebert, Natalie , Turner, Stephen T. , Eriksen, Björn O. , Rule, Andrew D. , Delanaye, Pierre , Schaeffner, Elke , Selistre, Luciano , Ebert, Natalie

Nephrology Dialysis Transplantation | November 16, 2016 | Volume: 32 | Issue: 3 | Pages: 497-507

10.1093/ndt/gfw425 | PMID 28089986 Get It

Abstract Background. We recently published and validated the new serum creatinine (Scr)-based full-age-spectrum equation (FAScrea) for estimating the glomerular filtration rate (GFR) for healthy and kidney–diseased subjects of all ages. The equation was based on the concept of normalized Scr and shows equivalent to superior prediction performance to the currently recommended equations for children, adolescents, adults and older adults. Methods. Based on an evaluation of the serum cystatin C (ScysC) distribution, we defined normalization constants for ScysC (QcysC = 0.82 mg/L for ages &lt;70 years and QcysC = 0.95 mg/L for ages ≥70 years). By replacing Scr/Qcrea in the FAScrea equation with ScysC/QcysC, or with the average of both normalized biomarkers, we obtained new ScysC-based (FAScysC) and combined Scr-/ScysC-based FAS equations (FAScombi). To validate the new FAScysC and FAScombi we collected data on measured GFR, Scr, ScysC, age, gender, height and weight from 11 different cohorts including n = 6132 unique white subjects (368 children, aged ≤18 years, 4295 adults and 1469 older adults, aged ≥70 years). Results. In children and adolescents, the new FAScysC equation showed significantly better performance [percentage of patients within 30% of mGFR (P30) = 86.1%] than the Caucasian Asian Paediatric Adult Cohort equation (P30 = 76.6%; P &lt; 0.0001), or the ScysC-based Schwartz equation (P30 = 68.8%; P &lt; 0.0001) and the FAScombi equation outperformed all equations with P30 = 92.1% (P &lt; 0.0001). In adults, the FAScysC equation (P30 = 82.6%) performed equally as well as the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPIcysC) (P30 = 80.4%) and the FAScombi equation (P30 = 89.9%) was also equal to the combined CKD-EPI equation (P30 = 88.2%). In older adults, FAScysC was superior (P30 = 88.2%) to CKD-EPIcysC (P30 = 84.4%; P &lt; 0.0001) and the FAScombi equation (P30 = 91.2%) showed significantly higher performance than the combined CKD-EPI equation (P30 = 85.6%) (P &lt; 0.0001). Conclusion. The FAS equation is not only applicable to all ages, but also for all recommended renal biomarkers and their combinations.
Specificity of B-Type Natriuretic Peptide Assays: Cross-Reactivity with Different BNP, NT-proBNP, and proBNP Peptides
Saenger, Amy K., Rodríguez‐Fraga, Olaia, Ler, Ranka, Ordóñez‐Llanos, Jordi , Jaffe, Allan S. , Goetze, Jens P. , Apple, Fred S. , Jaffe, Allan S.

Clinical Chemistry | November 16, 2016 | Volume: 63 | Issue: 1 | Pages: 351-358

10.1373/clinchem.2016.263749 | PMID 28062628 Get It

AbstractBACKGROUNDB-type natriuretic peptides (BNPs) are used clinically to diagnose and monitor heart failure and are present in the circulation as multiple proBNP-derived fragments. We investigated the specificity of BNP immunoassays with glycosylated and nonglycosylated BNP, N-terminal proBNP (NT-proBNP), and proBNP peptides to probe the cross-reactivity of each assay.METHODSNine B-type natriuretic peptides were studied,including synthetic and recombinant BNP (Shionogi, Scios, Mayo), human and synthetic glycosylated and nonglycosylated NT-proBNP (HyTest, Roche Diagnostics), and human glycosylated and nonglycosylated proBNP (HyTest, Scios). Five BNP [Abbott, Abbott POC, Alere, Beckman Coulter, Siemens (Centaur)], 9 NT-proBNP [Ortho-Clinical Diagnostics, Roche, Response, bioMerieux, Siemens (Dimension, Immulite, Stratus CS), Mitsubishi] and 3 research-use-only proBNP immunoassays [Biosite (Alere), Bio-Rad, Goetze] were evaluated. Specificity was assessed by calculating the recovery between baseline and peptide-spiked human plasma pools at target concentrations of 100 ng/L BNP, 300 ng/L proBNP, or 450 ng/L NT-proBNP. All assays were performed in duplicate.RESULTSBNP and NT-proBNP assays demonstrated substantial cross-reactivity with proBNP peptides. NT-proBNP assays do not detect glycosylated forms of either NT-proBNP or proBNP. proBNP assays preferentially detect the BNP 1–32 peptide and have minimal cross-reactivity with BNP peptides and glycosylated proBNP.CONCLUSIONSBNP or NT-proBNP results are not transferable among the current existing immunoassays owing to their differences in cross-reactivity and ability to detect various glycosylated forms of proBNP-derived fragments. Opportunities remain to standardize and harmonize BNP and NT-proBNP assays, as well as to develop specific proBNP assays, to widen their clinical scope of use.